{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:21:48Z","timestamp":1760908908720,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000869","name":"Susan G. Komen for the Cure","doi-asserted-by":"publisher","award":["M124188\/BCTR0707898"],"award-info":[{"award-number":["M124188\/BCTR0707898"]}],"id":[{"id":"10.13039\/100000869","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s10549-015-3292-8","type":"journal-article","created":{"date-parts":[[2015,2,17]],"date-time":"2015-02-17T09:19:33Z","timestamp":1424164773000},"page":"157-167","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy"],"prefix":"10.1007","volume":"150","author":[{"given":"Carlos","family":"Acevedo-Gadea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos","family":"Hatzis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gina","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal","family":"Fishbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Lezon-Geyda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Zelterman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"DiGiovanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyndsay","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maysa M.","family":"Abu-Khalaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,17]]},"reference":[{"issue":"11","key":"3292_CR1","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783\u2013792. doi:10.1056\/NEJM200103153441101","journal-title":"N Engl J Med"},{"issue":"10","key":"3292_CR2","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","volume":"26","author":"AD Seidman","year":"2008","unstructured":"Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26(10):1642\u20131649. doi:10.1200\/JCO.2007.11.6699","journal-title":"J Clin Oncol"},{"issue":"7","key":"3292_CR3","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1200\/JCO.2009.24.2024","volume":"28","author":"J Baselga","year":"2010","unstructured":"Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28(7):1138\u20131144. doi:10.1200\/JCO.2009.24.2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"3292_CR4","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","volume":"28","author":"KL Blackwell","year":"2010","unstructured":"Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O\u2019Shaughnessy J (2010) Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28(7):1124\u20131130. doi:10.1200\/JCO.2008.21.4437","journal-title":"J Clin Oncol"},{"issue":"8","key":"3292_CR5","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1038\/sj.bjc.6602162","volume":"91","author":"S Chan","year":"2004","unstructured":"Chan S (2004) Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 91(8):1420\u20131424. doi:10.1038\/sj.bjc.6602162","journal-title":"Br J Cancer"},{"issue":"14","key":"3292_CR6","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1200\/JCO.2011.37.4207","volume":"30","author":"J Cortes","year":"2012","unstructured":"Cortes J, Fumoleau P, Bianchi GV, Petrella TM, Gelmon K, Pivot X, Verma S, Albanell J, Conte P, Lluch A, Salvagni S, Servent V, Gianni L, Scaltriti M, Ross GA, Dixon J, Szado T, Baselga J (2012) Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30(14):1594\u20131600. doi:10.1200\/JCO.2011.37.4207","journal-title":"J Clin Oncol"},{"issue":"1","key":"3292_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25\u201332. doi:10.1016\/S1470-2045(11)70336-9","journal-title":"Lancet Oncol"},{"issue":"9","key":"3292_CR8","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1586\/14737140.7.9.1183","volume":"7","author":"GM Higa","year":"2007","unstructured":"Higa GM, Abraham J (2007) Lapatinib in the treatment of breast cancer. Expert Rev Anticancer Ther 7(9):1183\u20131192. doi:10.1586\/14737140.7.9.1183","journal-title":"Expert Rev Anticancer Ther"},{"issue":"6","key":"3292_CR9","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/01.cco.0000143964.74936.d1","volume":"16","author":"EK Rowinsky","year":"2004","unstructured":"Rowinsky EK (2004) Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol 16(6):564\u2013575","journal-title":"Curr Opin Oncol"},{"issue":"4","key":"3292_CR10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","volume":"12","author":"K Berns","year":"2007","unstructured":"Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R (2007) A functional genetic approach identifies the PI3\u00a0K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12(4):395\u2013402. doi:10.1016\/j.ccr.2007.08.030","journal-title":"Cancer Cell"},{"issue":"2","key":"3292_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","volume":"6","author":"Y Nagata","year":"2004","unstructured":"Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6(2):117\u2013127. doi:10.1016\/j.ccr.2004.06.022","journal-title":"Cancer Cell"},{"issue":"19","key":"3292_CR12","doi-asserted-by":"publisher","first-page":"5883","DOI":"10.1158\/1078-0432.CCR-06-2837","volume":"13","author":"CH Lu","year":"2007","unstructured":"Lu CH, Wyszomierski SL, Tseng LM, Sun MH, Lan KH, Neal CL, Mills GB, Hortobagyi GN, Esteva FJ, Yu D (2007) Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 13(19):5883\u20135888. doi:10.1158\/1078-0432.CCR-06-2837","journal-title":"Clin Cancer Res"},{"issue":"17","key":"3292_CR13","doi-asserted-by":"publisher","first-page":"7066","DOI":"10.1158\/0008-5472.CAN-08-0922","volume":"68","author":"CH Squarize","year":"2008","unstructured":"Squarize CH, Castilho RM, Gutkind JS (2008) Chemoprevention and treatment of experimental Cowden\u2019s disease by mTOR inhibition with rapamycin. Cancer Res 68(17):7066\u20137072. doi:10.1158\/0008-5472.CAN-08-0922","journal-title":"Cancer Res"},{"issue":"23","key":"3292_CR14","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1200\/JCO.2010.32.2321","volume":"29","author":"PK Morrow","year":"2011","unstructured":"Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, Xiong Y, Zhang S, Krop IE, Winer EP, Kindelberger DW, Coviello J, Sahin AA, Nunez R, Hortobagyi GN, Yu D, Esteva FJ (2011) Phase I\/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol 29(23):3126\u20133132. doi:10.1200\/JCO.2010.32.2321","journal-title":"J Clin Oncol"},{"issue":"34","key":"3292_CR15","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1200\/JCO.2009.27.8549","volume":"28","author":"F Andre","year":"2010","unstructured":"Andre F, Campone M, O\u2019Regan R, Manlius C, Massacesi C, Sahmoud T, Mukhopadhyay P, Soria JC, Naughton M, Hurvitz SA (2010) Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 28(34):5110\u20135115. doi:10.1200\/JCO.2009.27.8549","journal-title":"J Clin Oncol"},{"issue":"2","key":"3292_CR16","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10549-010-1260-x","volume":"125","author":"G Jerusalem","year":"2011","unstructured":"Jerusalem G, Fasolo A, Dieras V, Cardoso F, Bergh J, Vittori L, Zhang Y, Massacesi C, Sahmoud T, Gianni L (2011) Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 125(2):447\u2013455. doi:10.1007\/s10549-010-1260-x","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"3292_CR17","first-page":"295","volume":"3","author":"S Huang","year":"2002","unstructured":"Huang S, Houghton PJ (2002) Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs 3(2):295\u2013304","journal-title":"Curr Opin Investig Drugs"},{"issue":"18","key":"3292_CR18","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1038\/sj.onc.1207542","volume":"23","author":"DC Fingar","year":"2004","unstructured":"Fingar DC, Blenis J (2004) Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23(18):3151\u20133171. doi:10.1038\/sj.onc.1207542","journal-title":"Oncogene"},{"issue":"14","key":"3292_CR19","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1056\/NEJMp038141","volume":"349","author":"AR Marks","year":"2003","unstructured":"Marks AR (2003) Sirolimus for the prevention of in-stent restenosis in a coronary artery. N Engl J Med 349(14):1307\u20131309. doi:10.1056\/NEJMp038141","journal-title":"N Engl J Med"},{"issue":"17","key":"3292_CR20","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-12-0110","volume":"18","author":"EE Cohen","year":"2012","unstructured":"Cohen EE, Wu K, Hartford C, Kocherginsky M, Eaton KN, Zha Y, Nallari A, Maitland ML, Fox-Kay K, Moshier K, House L, Ramirez J, Undevia SD, Fleming GF, Gajewski TF, Ratain MJ (2012) Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. Clin Cancer Res 18(17):4785\u20134793. doi:10.1158\/1078-0432.CCR-12-0110","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3292_CR21","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1200\/JCO.2005.10.073","volume":"23","author":"S Braun","year":"2005","unstructured":"Braun S, Naume B (2005) Circulating and disseminated tumor cells. J Clin Oncol 23(8):1623\u20131626. doi:10.1200\/JCO.2005.10.073","journal-title":"J Clin Oncol"},{"issue":"7","key":"3292_CR22","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1200\/JCO.2005.08.140","volume":"23","author":"M Cristofanilli","year":"2005","unstructured":"Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, Fritsche HA, Hortobagyi GN, Terstappen LW (2005) Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 23(7):1420\u20131430. doi:10.1200\/JCO.2005.08.140","journal-title":"J Clin Oncol"},{"issue":"2","key":"3292_CR23","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s10549-012-2382-0","volume":"137","author":"M Wallwiener","year":"2013","unstructured":"Wallwiener M, Hartkopf AD, Baccelli I, Riethdorf S, Schott S, Pantel K, Marme F, Sohn C, Trumpp A, Rack B, Aktas B, Solomayer EF, Muller V, Janni W, Schneeweiss A, Fehm TN (2013) The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treat 137(2):503\u2013510. doi:10.1007\/s10549-012-2382-0","journal-title":"Breast Cancer Res Treat"},{"issue":"12 Pt 1","key":"3292_CR24","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1158\/1078-0432.CCR-03-0695","volume":"10","author":"KL Blackwell","year":"2004","unstructured":"Blackwell KL, Dewhirst MW, Liotcheva V, Snyder S, Broadwater G, Bentley R, Lal A, Riggins G, Anderson S, Vredenburgh J, Proia A, Harris LN (2004) HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. Clin Cancer Res 10(12 Pt 1):4083\u20134088. doi:10.1158\/1078-0432.CCR-03-0695","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3292_CR25","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1158\/1078-0432.CCR-0951-3","volume":"10","author":"GE Konecny","year":"2004","unstructured":"Konecny GE, Meng YG, Untch M, Wang HJ, Bauerfeind I, Epstein M, Stieber P, Vernes JM, Gutierrez J, Hong K, Beryt M, Hepp H, Slamon DJ, Pegram MD (2004) Association between HER-2\/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 10(5):1706\u20131716","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3292_CR26","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM, Group CS (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109\u2013119. doi:10.1056\/NEJMoa1113216","journal-title":"N Engl J Med"},{"issue":"6","key":"3292_CR27","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/S1470-2045(14)70138-X","volume":"15","author":"F Andre","year":"2014","unstructured":"Andre F, O\u2019Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M, Shen K, Litton J, Chen D, Zhang Y, Ali S, Taran T, Gianni L (2014) Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15(6):580\u2013591. doi:10.1016\/S1470-2045(14)70138-X","journal-title":"Lancet Oncol"},{"key":"3292_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28689","author":"RK Murthy","year":"2014","unstructured":"Murthy RK, Varma A, Mishra P, Hess KR, Young E, Murray JL, Koenig KH, Moulder SL, Melhem-Bertrandt A, Giordano SH, Booser D, Valero V, Hortobagyi GN, Esteva FJ (2014) Effect of adjuvant\/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer. doi:10.1002\/cncr.28689","journal-title":"Cancer"},{"issue":"8","key":"3292_CR29","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1634\/theoncologist.2009-0029","volume":"15","author":"JM Extra","year":"2010","unstructured":"Extra JM, Antoine EC, Vincent-Salomon A, Delozier T, Kerbrat P, Bethune-Volters A, Guastalla JP, Spielmann M, Mauriac L, Misset JL, Serin D, Campone M, Hebert C, Remblier C, Bergougnoux L, Campana F, Namer M (2010) Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist 15(8):799\u2013809. doi:10.1634\/theoncologist.2009-0029","journal-title":"Oncologist"},{"issue":"1\u20132","key":"3292_CR30","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.canlet.2007.10.043","volume":"260","author":"M Barok","year":"2008","unstructured":"Barok M, Balazs M, Nagy P, Rakosy Z, Treszl A, Toth E, Juhasz I, Park JW, Isola J, Vereb G, Szollosi J (2008) Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor. Cancer Lett 260(1\u20132):198\u2013208. doi:10.1016\/j.canlet.2007.10.043","journal-title":"Cancer Lett"},{"issue":"18S","key":"3292_CR31","first-page":"576","volume":"24","author":"P Spadaro","year":"2006","unstructured":"Spadaro P, Ingemi M, Dottore G, Toscano G, Maisano R (2006) Changes in circulating endothelial cells (CEL) in patients receiving trastuzumab for metastatic breast cancer predict response to treatment. J Clin Oncol 24(18S):576","journal-title":"J Clin Oncol"},{"issue":"8","key":"3292_CR32","first-page":"2887","volume":"9","author":"JM Peralba","year":"2003","unstructured":"Peralba JM, DeGraffenried L, Friedrichs W, Fulcher L, Grunwald V, Weiss G, Hidalgo M (2003) Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 9(8):2887\u20132892","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3292_CR33","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1158\/0008-5472.CAN-3554-2","volume":"64","author":"A Boulay","year":"2004","unstructured":"Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, Tobler S, Heusser C, O\u2019Reilly T, Stolz B, Marti A, Thomas G, Lane HA (2004) Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64(1):252\u2013261","journal-title":"Cancer Res"},{"issue":"10","key":"3292_CR34","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","volume":"26","author":"A O\u2019Donnell","year":"2008","unstructured":"O\u2019Donnell A, Faivre S, Burris HA 3rd, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26(10):1588\u20131595. doi:10.1200\/JCO.2007.14.0988","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-015-3292-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-015-3292-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-015-3292-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-015-3292-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T01:39:50Z","timestamp":1659058790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-015-3292-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["3292"],"URL":"https:\/\/doi.org\/10.1007\/s10549-015-3292-8","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"2 December 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}